Skip to main content

Rosemary Mazanet, Peter Lassota

Rosemary Mazanet has joined the board of directors of Cellumen, the company said last week.
Mazanet is currently CEO of Breakthrough Therapeutics and acting CEO of Access Pharmaceuticals. She has previously served as CSO and general partner of Oracle Partners, and as director of clinical research at Amgen. Mazanet is also a member of the board of trustees of the University of Pennsylvania School of Medicine, and serves on the boards of several public companies including GTx and Aksys.

Caliper this week said that it has appointed Peter Lassota as divisional vice president of oncology.
At Caliper, Lassota will lead the R&D activities involved in oncology applications and the utilization of biophotonic imaging for developing biomarker research technologies. Lassota joins Caliper from the Novartis Institutes for Biomedical Research, where he led Novartis’ US oncology pharmacology unit. Lassota has also worked at Wyeth-Ayerst Research and the American Cyanamid Company. He has an MS in chemistry from the University of Warsaw and a PhD in biochemistry and biophysics from the Polish Academy of Sciences.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.